Fc Protein and Glycoengineered Antibodies MarketFc Protein and Glycoengineered Antibodies Market to Reflect Steady Growth 2027

Fc Protein and Glycoengineered Antibodies
Market Size, Share, Trend, Outlook, Future
Growth Analysis And Synthesis 2019 - 2027
Monoclonal antibodies are developed by identical immune cells, which have a therapeutic use. The
crystallized fragments (Fc) protein and glycoengineered antibodies are known as the next generation
antibodies. These monoclonal antibodies are immunoglobulin G (IgG) type of molecules, which are
attached to a glycan residue on crystallisable fragment. Glycoengineering is the method by which these
antibodies are created. They have varied applications for the treatment of diseases such as multiple
sclerosis and cancers.
Ask Sample Copy of Research: https://www.coherentmarketinsights.com/insight/request-sample/2626
Global Fc Protein and Glycoengineered Antibodies Market Drivers
Key players in the market are focusing on research and development activities and receiving approvals
from regulatory bodies, which are expected to boost the global Fc protein and glycoengineered
antibodies market growth over the forecast period.
For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug Administration
(U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of urothelial carcinoma. In
March 2019, Tecentriq received its second approval from the U.S. FDA for the treatment of small lung
cancer. Furthermore, in November 2017, TG Therapeutics, Inc. began its clinical trial of Ublituximab for
the treatment of multiple sclerosis. It is currently in third phase of its clinical trial. Factors such as
increasing product approvals and robust pipeline are expected to drive the global fc protein and
glycoengineered antibodies market growth.
Global Fc Protein and Glycoengineered Antibodies Market Regional Analysis
North America region is expected to dominate in the global fc protein and glycoengineered antibodies
market due to factors such as product launches, presence of leading manufacturers (such as F. Hoffmann
La-Roche Ltd.), and active research and development in the field. Drugs such as Obinutuzumab (Gazyva),
Mogamulizumab (Poteligeo), Atezolizumab (Tecentriq), and Durvalumab (Imfinzi) have been approved in
the U.S. in 2013, 2018, 2016, and 2017 respectively.
Europe is expected to witness significant growth in the global Fc protein and glycoengineered antibodies
market. Factors such as approval for new drugs is expected to drive the Europe’s Fc protein and
glycoengineered antibodies market growth over the forecast period. For instance, in 2018, Kyowa Hakko
Kirin Co. Ltd. received an approval from the European Commission to market the Poteligeo antibody in
the European market. It is the first biological product that is being directed against chemokine receptor
4 (CCR4), which will be used for the treatment of Sezary syndrome that has been previously treated by
systemic therapy. Such new drug approvals are expected to propel Europe Fc protein and
glycoengineered antibodies market growth over the forecast period.
Report includes chapters which deeply display the following deliverable about industry :
• Fc Protein and Glycoengineered Antibodies Market Research Objective and Assumption
• Fc Protein and Glycoengineered Antibodies Market Purview - Report Description, Executive
Summary, and Coherent Opportunity Map (COM)
• Fc Protein and Glycoengineered Antibodies Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Fc Protein and Glycoengineered Antibodies Market, By Regions
• Fc Protein and Glycoengineered Antibodies Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and
Product Type.
• Fc Protein and Glycoengineered Antibodies Market Manufacturers Profiles/Analysis including
Company Basic Information, Manufacturing Base and Its Competitors.
• Fc Protein and Glycoengineered Antibodies Market Manufacturing Cost Analysis including Key
Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Fc Protein and Glycoengineered Antibodies Market Forecast including Production,
Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Global Fc Protein and Glycoengineered Antibodies Market Key Players
Some of the major players operating in the global Fc protein and glycoengineered antibodies market
include Kyowa Hakko Kirin Co. Ltd., Merck KGaA, Boehringer Ingelheim International GmbH,
AstraZeneca Plc, Amgen Inc., Genentech Inc., Five Prime Therapeutics Inc., Celldex Therapeutics, Clovis
Oncology, and TG Therapeutics, Inc.
Global Fc Protein and Glycoengineered Antibodies Market Taxonomy
The global Fc protein and glycoengineered antibodies market is segmented on the basis of drug,
application, and region.
By Drug
•
Approved Drugs
- Obinutuzumab (Gazyva)
- Mogamulizumab (Poteligeo)
- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
•
Pipeline Drugs
•
Ublituximab
•
Others
By Application
•
Oncology
•
Autoimmune Disease
•
Others
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/ongoinginsight/fc-protein-and-glycoengineered-antibodies-market-2626
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Increasing prevalence of diseases such as cancer is expected to propel the global Fc protein and glycoengineered antibodies market growth.